ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nurse Practitioner

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,972Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 349

$450K Total Retail Price of All Prescriptions

Rank: 30 out of 349

515 Patients Receiving at Least One Drug in Part D
58%Patients 65 Years and Older
76% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Carolina
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 515 patients filled at least one prescription for a schedule two drug, compared to an average of 10%.

Schedule Three
Controlled Substances

15% of this provider’s 515 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 4,315 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Carolina
OMEPRAZOLE 349 167 1 1
ZOLPIDEM TARTRATE 313 129 2 13
LISINOPRIL 290 154 3 3
FUROSEMIDE 280 155 4 6
HYDROCODONE-ACETAMINOPHEN 278 115 S3 5 2
OXYCODONE HCL-ACETAMINOPHEN 251 43 S2 6 27
SIMVASTATIN 239 157 7 4
POTASSIUM CHLORIDE 234 143 8 21
GABAPENTIN 205 58 9 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 185 99 10 28
AMLODIPINE BESYLATE 179 111 11 5
NEXIUM 175 65 12 20
LEVOTHYROXINE SODIUM 170 94 13 7
OXYCODONE-ACETAMINOPHEN 162 39 S2 14 26
METOPROLOL SUCCINATE 142 90 15 14
METFORMIN HCL ER 133 75 16 43
HYDROCHLOROTHIAZIDE 130 75 17 10
METOPROLOL TARTRATE 125 96 18 11
CYCLOBENZAPRINE HCL 122 31 R 19 34
METFORMIN HCL 111 54 20 9
PREDNISONE 104 55 21 30
PRAVASTATIN SODIUM 101 71 22 12
IBUPROFEN 100 25 23 99
GLIMEPIRIDE 98 49 24 50
RANITIDINE HCL 92 51 25 48
FLUTICASONE PROPIONATE 88 32 26 32
ALLOPURINOL 88 62 26 70
MELOXICAM 84 69 28 37
ATENOLOL 83 59 29 33
AMOX TR-POTASSIUM CLAVULANATE 76 39 30 134
PAROXETINE HCL 73 30 31 97
LOVASTATIN 73 36 31 55
NAPROXEN 71 36 33 141
WARFARIN SODIUM 70 28 34 19
CRESTOR 69 17 35 25
DIOVAN 65 27 36 73
LOSARTAN POTASSIUM 65 46 36 31
CARVEDILOL 63 33 38 23
AZITHROMYCIN 62 25 39 22
SERTRALINE HCL 61 47 40 24
DIOVAN HCT 61 11 40 118
PROAIR HFA 56 0 42 42
AMITRIPTYLINE HCL 54 29 R 43 79
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 9, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.